<ѻýҕl class="article_title">
Lean MASH Patients Face Higher Mortality and Worse Outcomes
ѻýҕl>
These data confirm that lean patients with MASH may be at greater risk of poor health outcomes than non-lean patients with MASH.
<ѻýҕl class="article_title">
MASLD Clinical Outcomes: Numerous, Dangerous
ѻýҕl>
Data on clinical outcomes in MASLD are lacking. This study’s goal was to provide a comprehensive meta-analysis of the longitudinal outcomes associated with MASLD.
<ѻýҕl class="article_title">
In MASLD, Which Serum Lipid-Soluble Micronutrients Heighten Risk?
ѻýҕl>
Serum lipid-soluble micronutrients, such as 25(OH)D and carotenoids, may be protective in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), whereas tocopherols may be associated with pathology, according to this report.
<ѻýҕl class="article_title">
Screening For MASH: How Accurate Are Non-Invasive Tests?
ѻýҕl>
Investigators reported on the clinical utility of several non-invasive screening methods to reduce the burden of invasive liver tissue sampling in patients at risk of MASH.
<ѻýҕl class="article_title">
Assessing MASH Risk in Older Adults with Diabetes
ѻýҕl>
Patients over age 50 with type 2 diabetes are at particular risk for metabolic dysfunction-associated steatohepatitis, according to the results of this study.
<ѻýҕl class="article_title">
MASLD in Lean Patients: What do We Know?
ѻýҕl>
This systematic review of the literature provides an interpretation of the new criteria related to lean MASLD.